Enzyme-Encapsulated Nanoparticles for Immune Shielding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current enzyme-based therapies for conditions like cancer and gout face challenges due to immune responses, toxicity, and limited circulation half-life, leading to ineffective delivery and rapid clearance of enzymes, which compromises treatment efficacy and increases side effects.

Innovation Solution

The development of enzyme-encapsulated nanoparticles, specifically synthetic hollow enzyme-loaded nanospheres (SHELS), which encapsulate enzymes within a shell structure with a hollow interior and porous external layer, preventing enzyme escape while allowing smaller molecules to pass through, thereby protecting enzymes from antibodies and maintaining bioactivity for targeted delivery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If enzymes are administered directly for therapy, then treatment can be provided, but immune responses occur and circulation half-life is limited

Engineering Contradiction:
Improvetreatment efficacyVSAvoidcirculation half-life
Core Design Contradiction:
ReliabilityVSDuration of action of moving object

Solution Approach 1:

The enzyme is encapsulated within the hollow interior region of the nanoparticle shell structure, creating a nested configuration where the therapeutic enzyme is protected inside the nanoparticle carrier. This nesting approach extends circulation half-life by shielding the enzyme from immune recognition while maintaining therapeutic functionality.

Inventive Principle:
Principle #7Nested doll (Nesting)

Solution Approach 2:

The nanoparticle employs a shell structure with an internal layer and external porous layer that acts as a protective barrier. This shell configuration extends enzyme circulation by preventing immune system access while allowing controlled substance transport through the porous external layer.

Inventive Principle:
Principle #30Flexible shells and thin films

2Adaptability or versatility

If enzymes are delivered systemically, then therapeutic coverage is achieved, but toxicity increases due to rapid clearance and immune response

Engineering Contradiction:
Improvetherapeutic coverageVSAvoidtoxicity
Core Design Contradiction:
Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The nanoparticle shell structure serves as an intermediary carrier between the immune system and the therapeutic enzyme. It mediates the delivery process by protecting the enzyme from immune attack while enabling controlled interaction with target tissues through the porous external layer, thereby reducing toxicity.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The hollow interior region of the nanoparticle creates an inert protective environment for the encapsulated enzyme, isolating it from harmful immune components in the bloodstream. This protected environment maintains enzyme stability and reduces immune-mediated toxicity during systemic circulation.

Inventive Principle:
Principle #39Inert atmosphere (Inert environment)

3Ease of operation

If the nanoparticle shell is made porous to allow substance exchange, then smaller molecules can pass through, but enzyme escape risk increases

Engineering Contradiction:
Improvesubstance exchange capabilityVSAvoidenzyme containment
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The shell structure exhibits different properties at different locations: the internal layer provides enzyme containment while the external layer is porous for substance exchange. This spatial differentiation of properties allows simultaneous achievement of enzyme containment and substance exchange functionality.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The external layer is constructed from porous material with controlled pore sizes that permit passage of small molecules and substrates while physically blocking the larger enzyme molecules. This porous structure enables selective transport based on molecular size, maintaining enzyme containment while allowing necessary substance exchange.

Inventive Principle:
Principle #31Porous materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the circulation and bioactivity of enzymes, reduces immune response, and achieves sustained therapeutic effects with reduced toxicity, enabling more effective and manageable treatment of conditions like cancer and gout by ensuring prolonged enzyme activity and targeted delivery.

Implementation Method 1

the porous material of the external layer is structured to prevent the enzyme from passing through the external layer while permitting a substance smaller than the enzyme to pass through the pores

Methodology Applied
Scientific EffectSize-based filtration: Filter (physical)

Implementation Method 2

the nanoscale structures are structured to initiate cavitation of microscale bubbles when ultrasonic acoustic energy is applied at the nanoparticle

Methodology Applied
Scientific EffectAcoustic cavitation: Acoustic Cavitation

Implementation Method 3

the enzyme contained within the interior region of the shell structure is structured to catalyze a reactive oxidative species (ROS) to decompose and produce oxygen inside the interior region

Methodology Applied
Scientific EffectEnzymatic catalysis: Catalysis

Implementation Method 4

a fluorophore attached to the shell structure and that emits an optical fluorescent signal based at least on the concentration of a chemical reactant or chemical product of a catalytic interaction

Methodology Applied
Scientific EffectFluorescence: Fluorescence

Data Source

PatentEP3046550B1Enzyme-encapsulated nanoparticle platform
Publication Date: 2020.04.15 DEVACELL
  • EP3046550B1 patent drawingFigure 1
  • EP3046550B1 patent drawingFigure 2
  • EP3046550B1 patent drawingFigure 3A~3B

AI summary

Disclosed are methods, systems, and devices for implementing nanoparticles to encapsulate biomolecules such as enzymes. In one aspect, a nanoparticle device includes a shell structure including an internal layer structured to enclose a hollow interior region and include one or more holes penetrating through the internal layer, and an external layer formed of a porous material around the internal layer; and an enzyme contained within the interior region of the shell structure, the enzyme having entered the shell structure through the one or more holes and incapable of passing through the external layer, in which the pores are of a size that prevents the enzyme to pass through the pores while permitting substances smaller than the pore size to pass through the pores.